Inositol versus Metformin administration in polycystic ovary syndrome patients: a case–control study
Abstract
Aim of the study The aim of this case–control study is to evaluate the clinical and biochemical efficiency of Inositol versus Metformin in polycystic ovary syndrome. Patients and methods The 128 patients who completed the study were divided into group A, which included 62 patients prescribed myo-inositol+D-chiro-inositol, two tabs per day, and group B, which included 66 patients prescribed Metformin 1500 mg per day for 3 months. Then, both groups were followed up for 3 months after the end of the treatment period. All patients underwent the following: baseline vaginal ultrasound, BMI and weight evaluation, Anti mullerian hormones (AMH) evaluation, serum progesterone, and Homeostasis Model of Assessment-Insulin Resistance (HOMA-IR), and were evaluated according to clinical and biochemical outcomes. Results Spontaneous menstruation and spontaneous pregnancy rate were significantly higher in group A than in group B: 46.7 and 11.2% in the Inositol group compared with 13.6 and 3.0% in the Metformin group. In terms of weight loss, the difference between both groups was significant in favor of the Inositol group. A significant difference was also detected in terms of a higher progesterone level in group A, whereas AMH and HOMA-IR showed insignificant differences in both groups. Conclusion Myo-inositol+D-chiro-inositol showed significantly better results in terms of weight reduction, resumption of spontaneous ovulation, and spontaneous pregnancy than Metformin in polycystic ovary…
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.